BioSpace News Archive

According to Emergen Research, the global antibody services market size was USD 1.41 Billion in 2020 and is expected to reach USD 3.30 Billion in 2028 and register a revenue CAGR of 11.1% during the forecast period, 2021-2028.

According to Emergen Research, the global durable medical equipment market size was USD 192.93 Billion in 2020 and is expected to reach USD 305.17 Billion in 2028 and register a revenue CAGR of 5.8% during the forecast period, 2021-2028.

According to Emergen Research, the global organs-on-chips market size was USD 27.5 Million in 2020 and is expected to reach USD 209.4 Million in 2028 and register a revenue CAGR of 28.1% during the forecast period, 2021-2028.

Increasing focus on personal appearance and grooming, technological advances in cosmetic surgical procedures, and rising preference for non-invasive cosmetic treatments are some of the key factors expected to drive market revenue growth over the upcoming years.

Growing geriatric population worldwide, rising cases of oral disorders, and increasing demand for advanced dental imaging solutions are among the key factors expected to drive market revenue growth during the forecast period.

Edenbridge’s first 505(b)(2) branded drug to be granted FDA approval.

Regulatory News: TRANSGENE (Paris:TNG) today announces that Management will participate in the upcoming investor events set out below.

Syntach AB in Lund, Sweden has been awarded € 2.5 million as a grant and part of blended finance of up to € 17,5 million from the European Innovation Council to support the development of its unique minimally invasive cardiac support system.

Genenta Science S.p.A., a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for solid tumors, including the lead product candidate, Temferon™, announced the closing of its upsized initial public offering of 2.4 million American Depositary Shares at a public offering price of $11.50 per ADS.

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Amgen and AstraZeneca’s Tezspire™ (tezepelumab-ekko) for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.